Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Trimmed by Chevy Chase Trust Holdings LLC

Key Points

• Chevy Chase Trust Holdings LLC reduced its holdings in Regeneron Pharmaceuticals by 6.5%, owning 206,728 shares valued at approximately $108.5 million after selling 14,482 shares.
• Regeneron Pharmaceuticals reported $12.89 EPS for the recent quarter, surpassing analysts' expectations of $8.43, with revenue reaching $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, reflecting a 0.6% yield and a payout ratio of 8.87%.

Chevy Chase Trust Holdings LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 206,728 shares of the biopharmaceutical company's stock after selling 14,482 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 0.19% of Regeneron Pharmaceuticals worth $108,532,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management grew its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Finally, Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.3%

Regeneron Pharmaceuticals stock opened at $569.17 on Friday. The business has a 50 day moving average price of $574.34 and a two-hundred day moving average price of $563.16. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock has a market cap of $60.33 billion, a price-to-earnings ratio of 14.34, a price-to-earnings-growth ratio of 1.85 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,013.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.56 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. Sanford C. Bernstein boosted their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 27th. Finally, Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.